Intellia Therapeutics, Inc. (NTLA)
Data as of , from SEC Form 4 filings.
See up to 3 months of NTLA. The 7-day demo opens the 1M and 3M ranges and puts NTLA on your watchlist.
Start 7-day demoData as of , from SEC Form 4 filings.
See up to 3 months of NTLA. The 7-day demo opens the 1M and 3M ranges and puts NTLA on your watchlist.
Start 7-day demo
Michael P. Dube - OfficerMichael P. Dube - Officer
James Basta - OfficerIntellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 4 | 32,650 | $401K |
36 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 2 of 2.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 William J. Chase | Open-market purchase | Common Stock | 100,000 | $10.03 | $1.00M | |
| Edward J. Dulac III - Officer | Open-market sale | Common Stock | 7,462 | $14.02 | $105K | |
| Michael P. Dube - Officer | Open-market sale | Common Stock | 2,503 | $9.95 | $25K | |
| Eliana Clark - Officer | Open-market sale | Common Stock | 1,022 | $9.82 | $10K | |
| Jesse Goodman | Open-market sale | Common Stock | 1,547 | $9.56 | $15K | |
| Jesse Goodman | Open-market sale | Common Stock | 1,547 | $9.23 | $14K | |
| Michael P. Dube - Officer | Open-market sale | Common Stock | 2,012 | $19.01 | $38K |
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Eliana Clark | Officer | 57,750 | $736K | View on EDGAR | |
| John M. Leonard | Officer, Director | 22,675 | $294K | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Intellia Therapeutics, Inc. (NTLA) had 3 insider filings in the last 90 days, with the most recent on 6 October 2026. The full record for NTLA runs to 36 Form 4 filings, the earliest from 4 October 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
No insider purchases of NTLA were filed in the last 90 days. 2 purchases are on record for this company.
4 insider sales of NTLA were filed in the last 90 days, totaling $401K.
This page collects NTLA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
